Pushing the Bounds of Science
Regeneron invests in genetic medicines and antibody platforms with some mRNA collaborations. Its broad R&D scale and commercial portfolio contrast with Kernal’s narrow, early-stage focus on in vivo CAR-T.
Free
End-to-end electric and autonomous road freight platform
robots for now, not someday.